Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Immunogenicity of Modified RNA Vaccines Against Influenza in Healthy Adults
NCT06436703Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of influenza modRNA vaccine in influenza, sponsored by Pfizer. Started May 2024; status: completed.
02
Drugs
influenza modRNA vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06436703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436703.